AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected ...

Q4 2025 Earnings Call Transcript July 15, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.13. Operator: Good morning, and welcome to the ...

A Capital Region manufacturer expects to continue growing its revenue over the next year, though its bottom line could take a ...

Fintel reports that on July 16, 2025, Lake Street initiated coverage of AngioDynamics (NasdaqGS:ANGO) with a Buy ...

Gain insights into AngioDynamics' Q4 2025 earnings, highlighting 12% revenue growth, international expansion, Med Tech advances, and a strong FY26 outlook.

AngioDynamics Inc (NASDAQ:ANGO) is set to release its Q4 2025 earnings on Jul 15, 2025. The consensus estimate for Q4 2025 ...

AngioDynamics now expects Med Tech revenue growth in the range of 14-16%, up from the earlier growth projection of 12-15% a year ago. Med Device revenue growth is projected to be flat.

AngioDynamics, Inc. ANGO reported an adjusted loss per share of 11 cents for first-quarter fiscal 2025, against the year-ago quarter’s adjusted loss per share of 12 cents.

AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day, as the company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Auryon and NanoKnife ...

Medical technology company AngioDynamics Inc is bucking what it calls an "extraordinary" effort by a rival company to recover hundreds of thousands of dollars in legal costs following its win at ...